Automation and Artificial Intelligence Are Reshaping Global Pharmacovigilance
Automation arrived in pharmacovigilance not as an optional strategic choice, but as an urgent response to a problem that has grown far beyond the limits of human capacity. The traditional model of manually processing adverse events — receiving reports by phone or email, manually entering data into safety databases, duplicating information entry, and relying solely on human reviewers to monitor inboxes — simply no longer works given the current volume of data.
In 2023, the FDA’s FAERS system recorded more than 2.1 million potential safety signals — a number that was roughly 780,000 back in 2011. That staggering growth is not just an impressive statistic: it represents real lives, complex clinical decisions, and a manual workflow that can no longer keep up with demand. Processing adverse event cases by hand is expensive, slow, and full of gaps. And when you consider that the World Health Organization estimates 134 million adverse events occur annually in hospital settings alone — contributing to 2.6 million preventable deaths each year — the scale of the problem becomes even clearer.
In the United States, recent analyses suggest that adverse drug events (ADEs) are now the third leading cause of death, with roughly 250,000 fatalities per year. Given this scenario, it is easy to understand why the pharmaceutical industry is racing to modernize its entire safety infrastructure. 💊
For large biopharmaceutical companies managing tens of thousands of cases per month, case processing activities can consume up to two-thirds of the total pharmacovigilance budget. Beyond cost, manual surveillance frequently misses critical safety signals hidden in unstructured data. The case for automation is not just compelling — it is existential.
The good news is that the technology has evolved quickly. What were once isolated pilot projects are now regulatory-validated enterprise platforms capable of transforming raw, scattered data into actionable insights at a speed no human team could achieve on its own. By 2026, cloud-native, Artificial Intelligence-centric safety platforms are turning raw, dispersed data into cohesive, practical information with unprecedented speed and accuracy.
The Collapse of the Manual Model and the Rise of Intelligent Platforms
For decades, pharmacovigilance ran on human teams reviewing adverse event reports one by one, extracting information from clinical documents, emails, medical records, and inconsistently filled-out forms. It was a process that demanded enormous time, enormous money, and still delivered results with a considerable margin of error. The volume of data was manageable — until it was not.
With the explosion of digital channels, social media, health apps, and integrated hospital systems, the volume of drug safety information multiplied at a pace no manual review-based model could keep up with. And the problem was not just the quantity. It was the nature of that data.
Most information relevant to patient safety is buried in unstructured data — free-text entries in electronic health records, posts on health forums, transcripts of calls to customer service centers, narrative reports from healthcare professionals. This data does not fit into spreadsheets, does not follow a fixed format, and cannot be processed efficiently by traditional systems. This is exactly where Artificial Intelligence stepped in to change the game for good.
The first automation initiatives in the industry were modest — simple filters, automated duplicate screening, basic rule-based alerts. But as language models advanced and specialized platforms matured, the industry realized it was possible to go much further.
Receive the best innovation content in your email.
All the news, tips, trends, and resources you're looking for, delivered to your inbox.
By subscribing to the newsletter, you agree to receive communications from Método Viral. We are committed to always protecting and respecting your privacy.
The Technology Landscape of Automation in 2026
The pharmacovigilance automation ecosystem spans several technology categories, each suited to specific stages of the adverse event lifecycle. The global pharmacovigilance automation market, valued at USD 3.03 billion in 2026, is expected to grow at a compound annual growth rate (CAGR) of 13.42%, reaching USD 5.68 billion by 2031. This growth is driven by the rapid adoption of AI and machine learning platforms, which accounted for more than 45% of implementations in 2025.
Let’s look at the key technologies driving this transformation:
Natural Language Processing (NLP)
Natural Language Processing is the fastest-growing technology segment in pharmacovigilance automation. It enables the rapid extraction of adverse events from unstructured sources such as medical literature, electronic health records, and clinical notes. AI systems fine-tuned for medical contexts have demonstrated the ability to reduce literature review time by 88% to 92%, while raising accuracy above 96%. This means an AI system can read an informally written clinical note from a physician, identify that the patient experienced an adverse reaction to a specific medication, and classify that information according to regulatory criteria required by agencies such as the FDA, EMA, or ANVISA. 🤖
Machine Learning and Deep Learning
Machine learning and deep learning algorithms are increasingly being used for severity assessment, signal detection, duplicate identification, and expectedness coding. By analyzing patterns in historical data, ML models can reduce false positive rates and identify potential safety signals months earlier than manual methods would allow. A safety signal is essentially a hypothesis — an association between a drug and an adverse event that was not previously documented or that appears with unusual frequency. Detecting these signals manually would require analysts to review hundreds of thousands of cases. With AI, this process is continuous and automated.
Robotic Process Automation (RPA)
RPA remains highly effective for automating routine, rule-based tasks such as email inbox monitoring, data entry, case registration, and follow-up routing. When combined with NLP, RPA creates a seamless pipeline from unstructured data capture to structured entry into safety databases. It is the kind of automation that eliminates operational bottlenecks without requiring major changes to the existing infrastructure.
Agentic AI and Generative AI
This is arguably the most significant evolution in pharmacovigilance automation. The integration of large language models (LLMs) enables the rapid synthesis of structured adverse event narratives from unstructured source documents, assists MedDRA coders with suggested preferred terms, and supports medical writing. Agentic AI — multi-agent systems where AI components manage subtasks autonomously — is emerging as a powerful tool for continuous, high-volume processing of global safety data. Approximately 73% of global pharmaceutical organizations are actively planning or deploying agentic AI between 2025 and 2026.
Regulators Are Evolving Too — And Fast
One of the most important aspects of this transformation is that it is not happening in a regulatory vacuum. As AI adoption accelerates, global regulators are actively shaping frameworks for its responsible use.
In January 2026, the FDA and EMA aligned on ten guiding principles for the responsible use of AI throughout the drug development lifecycle. These principles emphasize a human-centered, risk-based approach, with a focus on data governance, multidisciplinary expertise, and transparent model development. They build on the FDA’s 2025 preliminary guidelines on AI for regulatory decision support and the EMA’s earlier reflection papers.
In parallel, the Council for International Organizations of Medical Sciences (CIOMS), through Working Group XIV, published a comprehensive international framework for AI in pharmacovigilance in December 2025. The CIOMS report outlines seven core principles:
- Risk-based approach to oversight
- Human oversight, distinguishing between human-in-the-loop and human-on-the-loop systems
- Validity and robustness in real-world settings
- Transparency and explainability
- Data privacy by design
- Equity and fairness to mitigate algorithmic bias
- Governance and accountability throughout the entire AI lifecycle
The message is clear: AI use is welcome, as long as it is transparent, validated, and auditable. Black-box models that cannot explain the logic behind a classification are not suitable for regulatory use. Additionally, the new ICH E2D(R1) and M14 guidelines, effective from March 2026, require structured electronic formats, reinforcing the need for validated and interoperable systems. 📋
In Brazil, ANVISA has also been tracking this evolution and has signaled interest in aligning its guidelines with international standards. Companies operating in the Brazilian market that need to report adverse events to the agency are increasingly investing in platforms that support both local and international requirements, especially those with products registered in multiple markets. Automated regulatory compliance — the ability to automatically generate reports in the correct format for each agency — is now one of the top competitive differentiators in the industry.
The Three Pillars of a Successful Implementation
Implementing automation and Artificial Intelligence in pharmacovigilance is not simply a matter of subscribing to a platform and pressing a button. It is a process that involves cultural change, team upskilling, legacy system integration, and a clear data governance strategy. Research into successful programs — such as Sanofi’s ARTEMIS Project, which aims to reduce operational expenditure by 50% by 2027 while managing 700,000 cases per year — consistently reveals three foundational pillars.
Pillar 1 — Selection and Implementation Strategy
The most important decision a pharmacovigilance leadership team makes is defining and prioritizing the specific problem it is solving. Successful organizations start with a clearly articulated vision connected to business objectives such as compliance acceleration or cost-per-case reduction. In 2026, GxP-validated cloud-native SaaS platforms dominate the market. Organizations that prioritize architectural compatibility, API interoperability, and regulatory jurisdictional coverage achieve significantly better outcomes than those focused solely on feature lists. Vendor relationships are also shifting — from transactional purchases to co-innovation partnerships.
Pillar 2 — Operating Model Transformation
Automation should not simply speed up existing processes — it should fundamentally change which processes exist. The highest-value implementations begin with rigorous process reengineering, mapping current workflows, identifying non-value-adding activities, and eliminating them before applying automation. Process mining tools provide data-driven visibility into actual case management patterns.
This transformation redefines the human-AI partnership. As routine tasks are automated, case processors shift from data entry roles to quality review and AI model oversight. Pharmacovigilance scientists and medical officers are freed to focus on benefit-risk assessment, complex signal management, and proactive pharmacoepidemiology. When this partnership works well, the results are impressive: smaller teams can process much larger case volumes with significantly higher quality. 💡
Pillar 3 — Communication and Training
Technology implementation failures in pharmacovigilance are rarely caused by the technology itself — they stem from inadequate stakeholder alignment and training gaps. Successful organizations establish multi-tiered governance structures and maintain open communication channels from the start of the project.
Proactive communication with regulators is essential. Sharing computerized system validation documentation, audit trail architecture, and human oversight protocols with health authorities reduces inspection risk and builds institutional trust. Training programs also need to be redesigned — teams no longer need to master manual data entry, but rather need to understand AI model logic, recognize potential hallucinations or biases, and confidently manage exceptional cases. Human experts remain the final authority on regulatory decisions.
Measuring What Matters — KPIs for Automated Pharmacovigilance
Reaping the benefits of intelligent pharmacovigilance requires a disciplined measurement framework. Organizations that define key performance indicators (KPIs) before implementation and track them rigorously consistently outperform their peers. Industry benchmarks from 2025 to 2026 reveal the profound impact of leading automation platforms on core pharmacovigilance metrics, including case processing time, error rates, cost per case, and signal detection speed.
Defining these metrics upfront allows organizations not only to measure return on investment but also to justify expanding the automation program to other areas of the business. It is the difference between implementing technology because it is trendy and implementing technology because it delivers results.
Global Barriers and How to Overcome Them
Despite the clear trajectory toward automated pharmacovigilance, several persistent barriers must be addressed to achieve large-scale global adoption. Mid-sized biopharmaceutical companies and regional affiliates often struggle with the upfront investment required for enterprise-grade AI platforms. Legacy safety databases — many of which have been extensively customized over decades — present significant integration challenges. Migrating historical data to new structured formats requires meticulous mapping to preserve the regulatory history and ensure data integrity.
Data privacy and cross-jurisdictional compliance also remain complex obstacles. Regulations such as the European Union’s GDPR and various national data localization laws complicate the implementation of unified global cloud solutions. Multilingual natural language processing models also need continuous training to mitigate biases and correctly interpret medical terminology across different languages and regional clinical practices.
To overcome these barriers, industry consortia and regulatory bodies are fostering greater collaboration. Initiatives focused on standardizing data formats, sharing anonymized safety datasets for model training, and developing open-source validation frameworks are lowering the barrier to entry. As technology vendors offer modular, scalable solutions, even smaller organizations can begin their automation journey with targeted, high-impact use cases.
The Role of Real-World Evidence in Modern Pharmacovigilance
The expansion of real-world evidence (RWE) is a major catalyst for intelligent pharmacovigilance. Traditional spontaneous reporting systems capture only a fraction of the drug safety landscape. By integrating data from electronic health records, claims databases, patient registries, and even wearable devices, pharmacovigilance teams can build a more comprehensive and continuous safety profile for marketed products.
AI and machine learning are particularly well-suited to analyzing these massive, heterogeneous datasets. ML algorithms can identify subtle, long-term adverse events or rare drug interactions that may not become apparent until a medication has been on the market for years. This capability is especially critical for advanced therapies, such as cell and gene therapies, where long-term safety monitoring is both a regulatory requirement and a clinical necessity.
The Future of Drug Safety Has Already Begun
The landscape taking shape over the coming years is one of consolidation. The technologies already exist, regulators are building the necessary frameworks, and companies that moved early are reaping real competitive advantages — in operational efficiency, data quality, and most importantly, in their ability to protect patients faster and more accurately.
Integrating Artificial Intelligence is not a luxury or a passing trend — it is a core capability for high-performing pharmacovigilance teams. The ultimate goal of these technologies is not merely cost reduction, but the strengthening of global patient safety. As AI systems evolve to fuse multimodal data — combining electronic health records, wearable devices, and scientific literature — pharmacovigilance is shifting from a reactive reporting function to a predictive, precision-driven discipline.
Guided by robust governance and human expertise, intelligent pharmacovigilance is opening a new chapter of impact, ensuring that tomorrow’s medications are monitored with the speed and precision they demand. The pharmacovigilance we know is being redesigned — and Artificial Intelligence is the engine driving this transformation. 🚀
